Finland

Key Insights

1
No psychedelic therapy is approved for routine patient use in Finland; access is limited to standard medicines such as ketamine/esketamine under normal prescribing or special authorisation routes.
2
Finland logs 10 trials, 0 active, and one research organisation; psilocybin, ketamine and esketamine dominate, with placebo as the main comparator.
3
Finland’s modern psychedelic science was seeded by the Finnish Association for Psychedelic Research, founded in 2016, which helped legitimise the field domestically.
4
Momentum comes from Åbo Akademi’s Psychedelics Research Network and its Steps22 project, explicitly aiming to prepare Finland’s first human psychedelic trial.

Medical Only (Private)

Reimbursed Care Access

Finland maintains a restrictive controlled‑substance regime: pharmaceutical esketamine (Spravato) is an authorised medicine in the EU and available in Finland under prescription and supervised administration, while generic ketamine is an established medical anaesthetic (and occasionally used off‑label in psychiatric emergency settings) but psychedelic classical compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca/DMT plant preparations, mescaline, and 2C‑X) are scheduled as narcotics with no routine medical reimbursement except in authorised clinical research. Reimbursement of any medicine in Finland is governed by decisions of the Pharmaceuticals Pricing Board (Hila) and Kela; some medicines require special permits from Fimea and individual reimbursement decisions or Hila listing to be reimbursable. [https://www.ema.europa.eu/en/medicines/human/EPAR/spravato|EMA Spravato EPAR] [https://finlex.fi/fi/lainsaadanto/2008/543|Finlex: Government decree on narcotics (543/2008)] [https://www.hila.fi/en/notices/reimbursable-authorized-medicinal-products-and-their-prices/|Hila: Reimbursable products and prices] [https://www.kela.fi/can-you-get-reimbursement-for-medicine-costs|Kela: Medicine reimbursement system].

Full guide →